Ultime notizie per Kamada (NASDAQ:KMDA) Azioni

Kamada

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Kamada Ltd

General

KMDA

CORRECTION: Kamada reported business operations on June 17, 2025.

Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>, TASE: KMDA.TA))), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that, while circumstances in the Middle East are evolving, the Company is continuing the operations and manufacturing at its Israeli facility focusing on business continuity, and based on its assessment, the global availability of its products is not expected to be interrupted.
"While events in the Middle East are evolving, the operations and ongoing manufacturing of our products continue as planned," said Amir London, Kamada's Chief Executive Officer. "Although our shipments from Israel may be temporarily affected by the current closing of the Israeli airspace, our distribution centers outside Israel, as well as our partners and distributors worldwide, have sufficient level of products available, and we do not foresee shortage in meeting client demands. We are focused on our business continuity and the well-being of all our employees and will continue to closely monitor the circumstances."

News

Kamada Assures Uninterrupted Drug Supply as Israeli Operations Continue Despite Middle East Tensions

Benchmark analyst Robert Wasserman reiterates Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) with a Buy and maintains $15 price target.

Price Target

Reiteration

Analyst Ratings

Benchmark Reiterates Buy on Kamada, Maintains $15 Price Target

Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) affirms FY2025 sales outlook from $178.00 million-$182.00 million to $178.00 million-$182.00 million vs $179.90 million estimate.

Guidance

Kamada Affirms FY2025 Sales Guidance of $178.00M-$182.00M vs $179.90M Est

Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) reported quarterly earnings of $0.07 per share which met the analyst consensus estimate. This is a 75 percent increase over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $44.02 million which beat the analyst consensus estimate of $42.23 million by 4.23 percent. This is a 16.65 percent increase over sales of $37.74 million the same period last year.

Earnings

Earnings Beats

Kamada Q1 EPS $0.07, Inline, Sales $44.02M Beat $42.23M Estimate

ADCT

AEVA

AFCG

ALUR

ARCO

ATER

AYTU

BCDA

BITF

BNGO

The Beachbody Company, Inc. Class A Common Stock

BODI

BOOT

BRTX

BZAI

CAAS

CANG

CCAP

CDXS

CELC

CLBT

CLSD

CREX

CSCO

CSPI

CSWC

CTSO

DAVA

DERM

DRIO

DYAI

EGAN

ELVA

EPSN

EWCZ

FIHL

FOSL

GCTS

GLBE

GROV

GWRS

HWKN

IBTA

ICCC

INVZ

IREN

ISSC

ITRG

JACK

KARO

KITT

KRNT

LAZR

LDTC

LIEN

LIQT

LOCL

LUCD

LUXE

LVLU

MDXH

MGRM

MMYT

NEXN

NSYS

NTWK

NVGS

NYXH

ONCY

PDSB

PYPD

RCAT

RDCM

REKR

RELI

RSKD

SBLK

SCPH

SDHC

SDOT

SDST

SGML

SHIM

Earnings Scheduled For May 14, 2025

Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-14. Here's what investors need to know before the announcement.
Analysts estimate that Kamada will report an earnings per share (EPS) of $0.07. 
Anticipation surrounds Kamada's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.02, which was followed by a 3.1% increase in the share price the next day.
Here's a look at Kamada's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.05</td>
<td>0.07</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.07</td>
<td>0.07</td>
<td>0.08</td>
<td>0.04</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-3.0%</td>
<td>1.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747162858_0.png" alt="eps graph" />
<h3>Performance of Kamada Shares</h3>
Shares of Kamada were trading at $6.82 as of May 12. Over the last 52-week period, shares are up 23.6%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/KMDA/earnings">To track all earnings releases for Kamada visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Kamada

Kamada Launches Post-Marketing Research Program For CYTOGAM

Benchmark analyst Robert Wasserman initiates coverage on Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) with a Buy rating and announces Price Target of $15.

Initiation

Benchmark Initiates Coverage On Kamada with Buy Rating, Announces Price Target of $15

Kamada Opens New Plasma Collection Center With Planned Annual Collection Capacity Of Approximately 50,000 Liters; Estimates Annual Revenue Contribution From Sales Of Normal Source Plasma  $8M-$10M At Full Capacity

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.
Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) fell sharply in today's pre-market trading after reporting topline results from two Phase 3 clinical trials of Povorcitinib in patients with Hidradenitis Suppurativa.
Incyte shares dipped 15.3% to $57.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) fell 13.8% to $16.00 in pre-market trading after jumping over 70% on Friday.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) dipped 12.1% to $44.01 in pre-market trading after gaining around 7% on Friday.</li>
<li>Tyra Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) fell 8.7% to $10.50 in pre-market trading after gaining 7% on Friday.</li>
<li>Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares dipped 4.4% to $8.05 in pre-market trading after gaining 7% on Friday.</li>
<li>Neogen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) fell 3.8% to $8.71 in pre-market trading.</li>
<li>Innventure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INV#NASDAQ">INV</a>) slipped 3.3% to $7.62 in pre-market trading.</li>
<li>Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) fell 3% to $6.77 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) slipped 1% to $ 247.77 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38311966/izea-worldwide-and-2-other-stocks-under-3-insiders-are-buying">IZEA Worldwide And 2 Other Stocks Under $3 Insiders Are Buying</a></li>
</ul>
Photo: Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

AFRM

INCY

NEOG

OMER

TSLA

TYRA

USAR

Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) with a Buy and maintains $11 price target.

HC Wainwright & Co. Reiterates Buy on Kamada, Maintains $11 Price Target

WIIM

Kamada shares are trading higher after the company reported better-than-expected Q4 EPS results and issued FY25 revenue guidance above estimates. Additionally, the company board approved a $0.20 per share special dividend.

Fiscal 2025 Guidance Kamada continues to expect to generate fiscal year 2025 total revenues in the range of $178 million to $182 million, and adjusted EBITDA in the range of $38 million to $42 million, representing a year-over-year increase of approximately 12% in revenues and 17% in adjusted EBITDA based on the mid-point of the 2025 guidance.

Kamada Reiterated FY25 Revenue Of $178M-$182M Vs $175.87M Est

Kamada Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>, TASE: KMDA.TA))), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that its Board of Directors has declared a special cash dividend of $0.20 (approximately NIS0.72) per share on the Company's ordinary shares (totaling approximately $11.5 million). The special cash dividend will be payable on April 7, 2025, to shareholders of record at the close of business on March 17, 2025.
 &nbsp;

Dividends

Kamada Board Approved Special Dividend Of $0.20/Share

Earnings Misses

Kamada Q4 2024 GAAP EPS $0.07 Beats $0.05 Estimate, Sales $39.005M Miss $39.447M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Full Truck Alliance Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YMM#NYSE">YMM</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $419.04 million. 
• Brown Forman Inc Class B Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is projected to report quarterly earnings at $0.46 per share on revenue of $1.07 billion. 
• CLPS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPS#NASDAQ">CLPS</a>) is estimated to report earnings for its first quarter. 
• EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) is expected to report quarterly loss at $0.48 per share on revenue of $11.02 million. 
• Kamada (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KMDA#NASDAQ">KMDA</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $39.59 million. 
• Editas Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDIT#NASDAQ">EDIT</a>) is expected to report quarterly loss at $0.58 per share on revenue of $19.97 million. 
• Hydrofarm Holdings Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYFM#NASDAQ">HYFM</a>) is likely to report quarterly loss at $2.00 per share on revenue of $41.10 million. 
• Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $300 thousand. 
• Global Ship Lease (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSL#NYSE">GSL</a>) is projected to report quarterly earnings at $2.54 per share on revenue of $171.17 million. 
• Broadwind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWEN#NASDAQ">BWEN</a>) is expected to report quarterly loss at $0.07 per share on revenue of $31.90 million. 
• Thor Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THO#NYSE">THO</a>) is likely to report quarterly earnings at $0.08 per share on revenue of $1.97 billion. 
• Caesarstone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTE#NASDAQ">CSTE</a>) is expected to report quarterly loss at $0.23 per share on revenue of $99.40 million. 
• REV Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REVG#NYSE">REVG</a>) is estimated to report quarterly earnings at $0.26 per share on revenue of $492.77 million. 
• Daktronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAKT#NASDAQ">DAKT</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $183.46 million. 
• Campbell`s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) is likely to report quarterly earnings at $0.73 per share on revenue of $2.74 billion. 
• Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $110.00 million. 
• VersaBank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VBNK#NASDAQ">VBNK</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $30.41 million. 
• OppFi (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OPFI#NYSE">OPFI</a>) is likely to report quarterly earnings at $0.14 per share on revenue of $133.50 million. 
• Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $90.36 million. 
• Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) is projected to report quarterly earnings at $1.35 per share on revenue of $201.09 million. 
• SmartRent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) is projected to report quarterly loss at $0.03 per share on revenue of $37.78 million. 
• Arbe Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBE#NASDAQ">ARBE</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $500 thousand. 
• Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) is likely to report quarterly earnings at $3.29 per share on revenue of $1.52 billion. 
• Brown Forman Inc Class A Common Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BF#NYSE">BF</a>) is estimated to report earnings for its third quarter. 
• Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) is projected to report quarterly earnings at $0.73 per share on revenue of $2.32 billion. 
• Stratasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSYS#NASDAQ">SSYS</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $149.88 million. 
<h3>Companies Reporting After The Bell</h3>
• Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) is projected to report quarterly earnings at $0.69 per share on revenue of $635.56 million. 
• Ring Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REI#AMEX">REI</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $86.72 million. 
• Vermilion Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VET#NYSE">VET</a>) is likely to report quarterly earnings at $1.67 per share on revenue of $507.35 million. 
• Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $62.00 million. 
• FRP Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRPH#NASDAQ">FRPH</a>) is likely to report earnings for its fourth quarter. 
• MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $172.52 million. 
• Miller Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLR#NYSE">MLR</a>) is likely to report quarterly earnings at $1.09 per share on revenue of $290.30 million. 
• Energy Transfer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) is estimated to report quarterly earnings at $0.21 per share on revenue of $128.69 million. 
• CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $102.50 million. 
• Alto Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTO#NASDAQ">ALTO</a>) is projected to report quarterly loss at $0.11 per share on revenue of $222.81 million. 
• Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) is projected to report quarterly loss at $481.50 per share on revenue of $400 thousand. 
• Park-Ohio Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PKOH#NASDAQ">PKOH</a>) is projected to report quarterly earnings at $0.62 per share on revenue of $405.85 million. 
• NACCO Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NC#NYSE">NC</a>) is expected to report earnings for its fourth quarter. 
• Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) is projected to report quarterly loss at $0.06 per share on revenue of $2.50 million. 
• Forge Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) is likely to report quarterly loss at $0.09 per share on revenue of $20.75 million. 
• Alta Equipment Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) is projected to report quarterly loss at $0.25 per share on revenue of $489.80 million. 
• Yext (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $112.77 million. 
• Methode Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) is projected to report quarterly loss at $0.10 per share on revenue of $262.60 million. 
• Ballys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) is likely to report quarterly loss at $0.17 per share on revenue of $612.38 million. 
• NN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNBR#NASDAQ">NNBR</a>) is likely to report quarterly loss at $0.06 per share on revenue of $108.60 million. 
• Climb Global Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLMB#NASDAQ">CLMB</a>) is likely to report quarterly earnings at $1.12 per share on revenue of $114.37 million. 
• Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) is expected to report quarterly loss at $0.13 per share on revenue of $13.13 million. 
• Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) is likely to report quarterly loss at $0.20 per share on revenue of $6.12 million. 
• Aware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AWRE#NASDAQ">AWRE</a>) is likely to report earnings for its fourth quarter. 
• LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) is likely to report quarterly loss at $0.05 per share on revenue of $68.13 million. 
• TriplePoint Venture Gwth (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPVG#NYSE">TPVG</a>) is projected to report quarterly earnings at $0.35 per share on revenue of $26.68 million. 
• Allient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNT#NASDAQ">ALNT</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $119.71 million. 
• ACRES Commercial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACR#NYSE">ACR</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $22.75 million. 
• Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) is estimated to report quarterly loss at $0.19 per share on revenue of $20.29 million. 
• Rayonier Adv Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYAM#NYSE">RYAM</a>) is expected to report quarterly loss at $0.19 per share on revenue of $418.50 million. 
• Amplify Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPY#NYSE">AMPY</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $76.54 million. 
• Grindr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) is expected to report quarterly earnings at $0.08 per share on revenue of $90.74 million. 
• LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) is estimated to report quarterly earnings at $0.63 per share on revenue of $237.32 million. 
• Sleep Number (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNBR#NASDAQ">SNBR</a>) is estimated to report quarterly loss at $0.23 per share on revenue of $389.75 million. 
• Fortuna Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSM#NYSE">FSM</a>) is estimated to report quarterly earnings at $0.20 per share on revenue of $308.00 million. 
• Banco BBVA Argentina (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAR#NYSE">BBAR</a>) is expected to report earnings for its fourth quarter. 
• Enhabit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHAB#NYSE">EHAB</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $259.11 million. 
• Global Water Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWRS#NASDAQ">GWRS</a>) is estimated to report quarterly earnings at $0.06 per share on revenue of $12.70 million. 
• Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $45.20 million. 
• Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) is expected to report quarterly earnings at $1.58 per share on revenue of $699.27 million. 
• Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) is estimated to report earnings for its fourth quarter. 
• MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) is likely to report quarterly earnings at $0.66 per share on revenue of $519.45 million. 
• Arq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARQ#NASDAQ">ARQ</a>) is estimated to report quarterly loss at $0.03 per share on revenue of $25.70 million. 
• Nine Energy Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NINE#NYSE">NINE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $135.00 million. 
• Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) is estimated to report quarterly earnings at $0.59 per share on revenue of $1.80 billion. 
• Descartes Systems Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGX#NASDAQ">DSGX</a>) is likely to report quarterly earnings at $0.56 per share on revenue of $169.38 million. 
• Kodiak Gas Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KGS#NYSE">KGS</a>) is likely to report quarterly earnings at $0.42 per share on revenue of $323.08 million. 
• LandBridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LB#NYSE">LB</a>) is estimated to report quarterly earnings at $0.32 per share on revenue of $38.04 million. 
• Riley Exploration Permian (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/REPX#AMEX">REPX</a>) is likely to report quarterly earnings at $1.64 per share on revenue of $105.49 million. 
• Pampa Energia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAM#NYSE">PAM</a>) is expected to report quarterly earnings at $0.72 per share on revenue of $450.71 million. 
• GeoPark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPRK#NYSE">GPRK</a>) is expected to report quarterly earnings at $0.80 per share on revenue of $168.00 million. 
• Orion Office REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONL#NYSE">ONL</a>) is likely to report earnings for its fourth quarter. 
• Silvaco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVCO#NASDAQ">SVCO</a>) is likely to report quarterly earnings at $0.13 per share on revenue of $19.62 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALNT

ALTG

ALTO

AMPY

AQST

ARBE

AWRE

BALY

BBAR

BWEN

CLMB

CLPS

CMPO

CSTE

CULP

DAKT

DSGX

EDIT

EHAB

EYPT

FRGE

FRPH

GPRK

GRND

HYFM

INVE

LPSN

MRVL

NINE

NNBR

OCGN

OPFI

PKOH

REPX

REVG

RGTI

RYAM

SGHT

SMRT

SNBR

SSYS

SVCO

TPVG

TREE

VBNK

VEEV

VSCO

YEXT

ZYME

Earnings Scheduled For March 5, 2025

Kamada shares are trading higher after the company announced a contract award for the supply of KAMRAB and VARIZIG in Latin America for 2025-2027.

Kamada announced that it was awarded a contract with an international organization for the supply of KAMRAB and VARIZIG in Latin America for 2025-2027

Health Care

Contracts

Press Releases

Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America

Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025

Kamada Declares Special Cash Dividend of $0.20 Per Share

Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth

Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas

Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders

Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025

Comments

Kamada

Notizie

Ultime notizie per Kamada (NASDAQ:KMDA) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO